Semaglutide and Cognition in Healthy Volunteers

Sponsor
University of Oxford
Study ID
NCT06363487
Status
Completed

Conditions

  • Cognitive Change

Eligibility Criteria

Sex
ALL
Age
21 Years - 55 Years
Healthy Volunteers
Accepted

Interventions

  • Semaglutide, 0.5 mg/mL — DRUG
    Injected subcutaneously (pre-filled pen) in the upper arm (preferred site), in the abdomen, or in the thigh according to participant's preference. The participant will be asked to wear an eye blindfold during the time of the study medication/placebo administration, to avoid compromising blinding. It is not possible to blind the researcher administering the medication/placebo because semaglutide comes in specific pre-filled pens. The person who administers the subcutaneous injection will be suitably trained and experienced, and have been authorised to do so by the Principal Investigator - they will not be involved in other aspects of the study for that participant to avoid compromising blinding.
  • Placebo, 0.9% NaCl 1.5mL — OTHER
    Injected subcutaneously (subcutaneous injection syringe) in the upper arm (preferred site), in the abdomen, or in the thigh according to participant's preference. The participant will be asked to wear an eye blindfold during the time of the study medication/placebo administration, to avoid compromising blinding. The person who administers the subcutaneous injection will be suitably trained and experienced, and have been authorised to do so by the Principal Investigator - they will not be involved in other aspects of the study for that participant to avoid compromising blinding.

Study Details

Semaglutide is a glucagon-like peptide 1 receptor agonist (GLP-1RA). It is a safe medication approved for use in type-2 diabetes mellitus (T2DM) and obesity. Primarily, it works by counteracting insulin-resistance and inducing weight loss. It also acts on several other interconnected neurobiological, immunological (esp. inflammatory), endocrine-metabolic, and gut-brain axis processes that play a role in depressive symptoms. Its effects on cognition and energy are currently unknown. In this study we are using semaglutide as an experimental tool to further investigate these relationships.

Key Dates

Start date
Jun 6, 2024
Status verified
Apr 2024
Primary completion
Dec 11, 2024
Completion
Dec 11, 2024

Study Design

Enrollment
70 participants (actual)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
BASIC_SCIENCE

Arms

  • Experimental: Semaglutide
    Semaglutide pre-filled pen, 0.5mg in 1.5mL, subcutaneous injection
  • Placebo Comparator: Placebo
    Saline solution 0.9% NaCl, solution for injection 1.5mL, subcutaneous injection syringe

Primary Outcome Measure

Reward (learning) [ Time Frame: 6-7 days ]

Related Studies